Examkin

Question

Difficulty: MediumEnd-of-Life and Palliative Care

A 66-year-old woman with metastatic breast cancer is receiving home hospice care. Over the past five days, her short-acting and long-acting oral morphine doses were significantly increased by the hospice team to manage escalating, diffuse bone pain. Her medical history is notable for hypertension and chronic kidney disease stage 3. Today, the hospice nurse evaluates the patient because her husband reports she has become increasingly restless and confused over the last 24 hours. He notes she was "picking at the air" and claiming there were insects on the wall. Furthermore, her pain appears worse; she grimaces and cries out even when a blanket lightly brushes against her legs. On examination, the patient is agitated and exhibits intermittent, spontaneous jerking movements of her upper and lower extremities. Vital signs show a temperature of 37.1°C (98.8°F), blood pressure of 110/70 mmHg, heart rate of 95/min, and respiratory rate of 16/min. Which of the following is the most appropriate next step in management?

  1. A
    Increase the current oral morphine dose to treat uncontrolled pain
  2. B
    Initiate oral haloperidol and maintain the current morphine regimen
  3. Discontinue morphine and start an alternative opioid at a reduced equianalgesic doseAnswer
  4. D
    Administer intravenous naloxone to reverse opioid toxicity
  5. E
    Revoke hospice care and arrange for hospital admission for a neurologic evaluation

Answer

The most appropriate step is to discontinue morphine and start an alternative opioid at a reduced equianalgesic dose.
The correct action is to discontinue morphine and start an alternative opioid at a reduced equianalgesic dose. This patient is exhibiting classic signs of opioid-induced neurotoxicity (OIN), characterized by the triad of myoclonus, delirium (hallucinations, confusion), and hyperalgesia (allodynia). Morphine is metabolized in the liver to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), which are excreted by the kidneys. In patients with chronic kidney disease, M3G can accumulate, causing severe neuroexcitation. The definitive treatment for OIN is opioid rotation—switching to an opioid with a different metabolic pathway or safer metabolite profile (such as fentanyl, methadone, or occasionally hydromorphone). When rotating opioids, the calculated equianalgesic dose must be reduced by 25% to 50% due to incomplete cross-tolerance between different opioid receptors.

Step-by-Step Solution

1
Evaluate the patient's new-onset symptoms of myoclonus, delirium, and allodynia.
Identify the clinical presentation as opioid-induced neurotoxicity (OIN).
These classic symptoms occurred following a significant morphine dose increase in a patient with underlying chronic kidney disease.
2
Determine the pathophysiologic mechanism of the toxicity.
Recognize that morphine's neurotoxic metabolite (morphine-3-glucuronide, M3G) has accumulated due to impaired renal clearance.
M3G lacks analgesic properties but causes neuroexcitation, leading to hyperalgesia and myoclonus.
3
Select the appropriate management strategy for OIN.
Choose opioid rotation and dose reduction.
Rotating to an opioid with safer pharmacokinetics in renal impairment (e.g., fentanyl, methadone) clears the offending metabolite. The dose must be reduced to account for incomplete cross-tolerance.

Key Concept

Opioid-Induced Neurotoxicity (OIN) and Opioid Rotation
Rate this question

Topics

End-of-Life and Palliative Care

More questions from this topic